Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Breast Cancer

Free Subscription Articles published in Int J Cancer Retrieve available abstracts of 125 articles: HTML format

Single Articles

May 2024
1. HAN X, Liu Y, Zhang S, Li L, et al
   Improving the diagnosis of ductal carcinoma in situ with microinvasion without immunohistochemistry: An innovative method with H&E-stained and multiphoton microscopy images.
   Int J Cancer. 2024;154:1802-1813.
   PubMed     Abstract available
   
   
   
2. BAO Y, Sui X, Wang X, Qu N, et al
   Extrachromosomal circular DNA landscape of breast cancer with lymph node metastasis.
   Int J Cancer. 2024 May 1. doi: 10.1002/ijc.34985.
   PubMed     Abstract available
   
   
   April 2024
3. BRANDT C, Vo JB, Gierach GL, Cheng I, et al
   Second primary cancer risks according to race and ethnicity among U.S. breast cancer survivors.
   Int J Cancer. 2024 Apr 29. doi: 10.1002/ijc.34971.
   PubMed     Abstract available
   
   
   
4. LIN YY, Gao HF, Li H, Hu Q, et al
   Clinical efficacy of tumor organoid-guided cancer therapy for locally advanced unresectable or metastatic breast cancer.
   Int J Cancer. 2024 Apr 5. doi: 10.1002/ijc.34945.
   PubMed     Abstract available
   
   
   
5. PEILA R, Rohan TE
   Circulating levels of biomarkers and risk of ductal carcinoma in situ of the breast in the UK Biobank study.
   Int J Cancer. 2024;154:1191-1203.
   PubMed     Abstract available
   
   
   
6. WANG Y, Cai W, He P, Cai Q, et al
   Clinical outcomes of coronavirus disease in patients with breast cancer treated with granulocyte colony-stimulating factor following chemotherapy: Triangulation of evidence using population-based cohort and Mendelian randomization analyses.
   Int J Cancer. 2024 Apr 1. doi: 10.1002/ijc.34914.
   PubMed     Abstract available
   
   
   March 2024
7. 
   Correction to "Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database".
   Int J Cancer. 2024 Mar 30. doi: 10.1002/ijc.34925.
   PubMed    
   
   
   
8. WU H, Wang W, Zhang Y, Chen Y, et al
   Establishment of patient-derived organoids for guiding personalized therapies in breast cancer patients.
   Int J Cancer. 2024 Mar 27. doi: 10.1002/ijc.34931.
   PubMed     Abstract available
   
   
   
9. SONGISO M, Nunez O, Cabanes A, Mutale M, et al
   Three-year survival of breast cancer patients attending a one-stop breast care clinic nested within a primary care health facility in sub-Saharan Africa-Zambia.
   Int J Cancer. 2024 Mar 25. doi: 10.1002/ijc.34920.
   PubMed     Abstract available
   
   
   
10. WANG T, Chai B, Chen WY, Holmes MD, et al
    Metformin and other anti-diabetic medication use and breast cancer incidence in the Nurses' Health Studies.
    Int J Cancer. 2024 Mar 22. doi: 10.1002/ijc.34917.
    PubMed     Abstract available
    
    
    
11. SCHMIDT ME, Maurer T, Behrens S, Seibold P, et al
    Cancer-related fatigue: Towards a more targeted approach based on classification by biomarkers and psychological factors.
    Int J Cancer. 2024;154:1011-1018.
    PubMed     Abstract available
    
    
    
12. KREGTING LM, Vrancken Peeters NJMC, Clarijs ME, Koppert LB, et al
    Health utility values of breast cancer treatments and the impact of varying quality of life assumptions on cost-effectiveness.
    Int J Cancer. 2024 Mar 13. doi: 10.1002/ijc.34899.
    PubMed     Abstract available
    
    
    
13. LUFTNER D, Schuetz F, Schneeweiss A, Hartkopf A, et al
    Efficacy and safety of everolimus plus exemestane in patients with hormone receptor-positive, HER-2-negative advanced breast cancer: Results from the open-label, multicentre, non-interventional BRAWO study.
    Int J Cancer. 2024 Mar 6. doi: 10.1002/ijc.34912.
    PubMed     Abstract available
    
    
    
14. LIU X, Xie X, Sui C, Liu X, et al
    Unraveling the cross-talk between N6-methyladenosine modification and non-coding RNAs in breast cancer: Mechanisms and clinical implications.
    Int J Cancer. 2024 Mar 1. doi: 10.1002/ijc.34900.
    PubMed     Abstract available
    
    
    February 2024
15. TANG T, Yu H, Xu S, Zhong Y, et al
    Causal effects of endometriosis on cancer risk: A Mendelian randomization study.
    Int J Cancer. 2024 Feb 7. doi: 10.1002/ijc.34876.
    PubMed     Abstract available
    
    
    
16. SVANOE AA, Humlevik ROC, Knutsvik G, Saele AKM, et al
    Age-related phenotypes in breast cancer: A population-based study.
    Int J Cancer. 2024 Feb 6. doi: 10.1002/ijc.34863.
    PubMed     Abstract available
    
    
    January 2024
17. RYBINSKA I, Mangano N, Romero-Cordoba SL, Regondi V, et al
    SAA1-dependent reprogramming of adipocytes by tumor cells is associated with triple negative breast cancer aggressiveness.
    Int J Cancer. 2024 Jan 30. doi: 10.1002/ijc.34859.
    PubMed     Abstract available
    
    
    
18. SHARMA MP, Shukla S, Misra G
    Recent advances in breast cancer cell line research.
    Int J Cancer. 2024 Jan 17. doi: 10.1002/ijc.34849.
    PubMed     Abstract available
    
    
    
19. JENSEN HAR, Horsbol TA, Thygesen LC, Davidsen M, et al
    Variations in the agreement of self-reported cancer: A Danish nationwide study.
    Int J Cancer. 2024;154:217-225.
    PubMed     Abstract available
    
    
    
20. CHEN H, Yang G, Ma J
    Ocular toxicity associated with anti-HER2 agents in breast cancer: A pharmacovigilance analysis using the FAERS database.
    Int J Cancer. 2024 Jan 12. doi: 10.1002/ijc.34848.
    PubMed     Abstract available
    
    
    
21. ZAHED H, Feng X, Sheikh M, Bray F, et al
    Age at diagnosis for lung, colon, breast and prostate cancers: An international comparative study.
    Int J Cancer. 2024;154:28-40.
    PubMed     Abstract available
    
    
    November 2023
22. 
    Retraction: Inhibition of Notch1 reverses EMT and chemoresistance to cisplatin via direct down-regulation of MCAM in triple-negative breast cancer cells. De Zeng, Yuan-Ke Liang, Ying-Sheng Xiao, Xiao-Long Wei, Hao-Yu Lin, Yang Wu, Jing-Wen Bai, Min Ch
    Int J Cancer. 2023 Nov 20. doi: 10.1002/ijc.34792.
    PubMed     Abstract available
    
    
    
23. JANSEN L, Schwettmann L, Behr C, Eberle A, et al
    Trends in cancer incidence by socioeconomic deprivation in Germany in 2007 to 2018: An ecological registry-based study.
    Int J Cancer. 2023;153:1784-1796.
    PubMed     Abstract available
    
    
    
24. RANGANATHAN S, Dee EC, Debnath N, Patel TA, et al
    Access and barriers to genomic classifiers for breast cancer and prostate cancer in India.
    Int J Cancer. 2023 Nov 14. doi: 10.1002/ijc.34784.
    PubMed     Abstract available
    
    
    
25. YANG F, Sun D, Ding C, Xia C, et al
    Global patterns of cancer transitions: A modelling study.
    Int J Cancer. 2023;153:1612-1622.
    PubMed     Abstract available
    
    
    October 2023
26. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    Reply to: Comments on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34772.
    PubMed    
    
    
    
27. CHEN H, Feng L
    Comment on "(Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer".
    Int J Cancer. 2023 Oct 31. doi: 10.1002/ijc.34770.
    PubMed    
    
    
    
28. YU Z, Dong X, Song M, Xu A, et al
    Targeting UBR5 inhibits postsurgical breast cancer lung metastases by inducing CDC73 and p53 mediated apoptosis.
    Int J Cancer. 2023 Oct 19. doi: 10.1002/ijc.34769.
    PubMed     Abstract available
    
    
    
29. RUGO HS, Liu X, Li B, McRoy L, et al
    Real-world treatment patterns for palbociclib plus an aromatase inhibitor, or an aromatase inhibitor alone, for patients with metastatic breast cancer in the Flatiron Database.
    Int J Cancer. 2023 Oct 13. doi: 10.1002/ijc.34748.
    PubMed     Abstract available
    
    
    
30. ZEVERIJN LJ, Looze EJ, Thavaneswaran S, van Berge Henegouwen JM, et al
    Limited clinical activity of palbociclib and ribociclib monotherapy in advanced cancers with cyclin D-CDK4/6 pathway alterations in the Dutch DRUP and Australian MoST trials.
    Int J Cancer. 2023;153:1413-1422.
    PubMed     Abstract available
    
    
    September 2023
31. HYUNG J, Lee SB, Kim J, Kim HJ, et al
    21-gene expression assay and clinical outcomes of premenopausal patients with hormone receptor-positive breast cancer.
    Int J Cancer. 2023 Sep 17. doi: 10.1002/ijc.34728.
    PubMed     Abstract available
    
    
    
32. DHOKOTERA TG, Muchengeti M, Davidovic M, Rohner E, et al
    Gynaecologic and breast cancers in women living with HIV in South Africa: A record linkage study.
    Int J Cancer. 2023 Sep 8. doi: 10.1002/ijc.34712.
    PubMed     Abstract available
    
    
    
33. LIU J, He M, Ou K, Wang X, et al
    Efficacy and safety of apatinib combined with dose-dense paclitaxel and carboplatin in neoadjuvant therapy for locally advanced triple-negative breast cancer: A prospective cohort study with propensity-matched analysis.
    Int J Cancer. 2023 Sep 7. doi: 10.1002/ijc.34717.
    PubMed     Abstract available
    
    
    August 2023
34. LIGORIO F, Lobefaro R, Fuca G, Provenzano L, et al
    Adding fasting-mimicking diet to first-line carboplatin-based chemotherapy is associated with better overall survival in advanced triple-negative breast cancer patients: A subanalysis of the NCT03340935 trial.
    Int J Cancer. 2023 Aug 24. doi: 10.1002/ijc.34701.
    PubMed     Abstract available
    
    
    
35. MAKHETHA M, Chabilal N, Aldous C
    Recent trends in hereditary breast cancer incidence by race and age in KwaZulu-Natal, South Africa: An 11-year single-centre retrospective study (2011-2021).
    Int J Cancer. 2023 Aug 14. doi: 10.1002/ijc.34687.
    PubMed     Abstract available
    
    
    
36. ALLALI S, Carton M, Everhard S, Rivera S, et al
    CANTO skin: Evaluation of skin toxicity risk factors in patients treated for breast cancer.
    Int J Cancer. 2023 Aug 12. doi: 10.1002/ijc.34664.
    PubMed     Abstract available
    
    
    
37. 
    Correction to Breast cancer rate after oophorectomy: A Prospective Danish Cohort Study.
    Int J Cancer. 2023 Aug 8. doi: 10.1002/ijc.34653.
    PubMed    
    
    
    
38. LI Y, Tong Z, Wu X, Ouyang Q, et al
    Real-world treatment patterns and outcomes of pyrotinib-based therapy in patients with HER2-positive advanced breast cancer (PRETTY): A nationwide, prospective, observational study.
    Int J Cancer. 2023 Aug 6. doi: 10.1002/ijc.34676.
    PubMed     Abstract available
    
    
    July 2023
39. ROCHE ME, Ko YH, Domingo-Vidal M, Lin Z, et al
    TP53 Induced Glycolysis and Apoptosis Regulator and Monocarboxylate Transporter 4 drive metabolic reprogramming with c-MYC and NFkB activation in breast cancer.
    Int J Cancer. 2023 Jul 27. doi: 10.1002/ijc.34660.
    PubMed     Abstract available
    
    
    
40. ROSAS JC, Aguado-Barrera ME, Azria D, Briers E, et al
    (Pre)treatment risk factors for late fatigue and fatigue trajectories following radiotherapy for breast cancer.
    Int J Cancer. 2023 Jul 5. doi: 10.1002/ijc.34640.
    PubMed     Abstract available
    
    
    June 2023
41. BEDDOK A, Mouren V, Cottu P, Laki F, et al
    Outcomes and toxicity of concurrent CDK4/6 inhibitor and locoregional radiotherapy for patients with de novo metastatic breast cancer.
    Int J Cancer. 2023 Jun 28. doi: 10.1002/ijc.34562.
    PubMed     Abstract available
    
    
    
42. SCHMIDT ME, Chong M, Klassen O, Wiskemann J, et al
    Longitudinal associations of bioelectrical phase angle and fatigue in breast cancer patients.
    Int J Cancer. 2023 Jun 20. doi: 10.1002/ijc.34630.
    PubMed     Abstract available
    
    
    
43. NAIMO GD, Forestiero M, Paoli A, Malivindi R, et al
    ERalpha/LKB1 complex upregulates E-cadherin expression and stimulates breast cancer growth and progression upon adiponectin exposure.
    Int J Cancer. 2023 Jun 16. doi: 10.1002/ijc.34626.
    PubMed     Abstract available
    
    
    
44. PAGANO C, di Zazzo E, Avilia G, Savarese B, et al
    Advances in "adiponcosis": Insights in the inner mechanisms at the base of adipose and tumour tissues interplay.
    Int J Cancer. 2023;152:2464-2473.
    PubMed     Abstract available
    
    
    
45. JIANG M, Liu J, Li Q, Xu B, et al
    The trichotomy of HER2 expression confers new insights into the understanding and managing for breast cancer stratified by HER2 status.
    Int J Cancer. 2023 Jun 14. doi: 10.1002/ijc.34570.
    PubMed     Abstract available
    
    
    
46. ROMANENS L, Chaskar P, Marcone R, Ryser S, et al
    Clonal expansion of intra-epithelial T cells in breast cancer revealed by spatial transcriptomics.
    Int J Cancer. 2023 Jun 12. doi: 10.1002/ijc.34620.
    PubMed     Abstract available
    
    
    
47. RAJKOVIC SM, Charalambous MP, Charalambous CP, Simic LD, et al
    Higher rate of progesterone receptor positivity in skeletal metastases of breast cancer with a pathological fracture vs those without fracture.
    Int J Cancer. 2023 Jun 2. doi: 10.1002/ijc.34605.
    PubMed     Abstract available
    
    
    
48. WITHROW DR, Nicholson BD, Morris EJA, Wong ML, et al
    Age-related differences in cancer relative survival in the United States: A SEER-18 analysis.
    Int J Cancer. 2023;152:2283-2291.
    PubMed     Abstract available
    
    
    
49. GABRIELSON M, Hammarstrom M, Backlund M, Bergqvist J, et al
    Effects of tamoxifen on normal breast tissue histological composition: Results from a randomised six-arm placebo-controlled trial in healthy women.
    Int J Cancer. 2023;152:2362-2372.
    PubMed     Abstract available
    
    
    May 2023
50. KUANG X, Luo Z, Sun Z, Hu J, et al
    Distinct invasive patterns in situ between estrogen receptor-positive and triple-negative breast cancer through the intraductal tracking of carbon nanoparticles.
    Int J Cancer. 2023 May 31. doi: 10.1002/ijc.34611.
    PubMed     Abstract available
    
    
    
51. SONG H, Jung YS, Tran TXM, Moon CM, et al
    Increased risk of pancreatic, thyroid, prostate and breast cancers in men with a family history of breast cancer: A population-based study.
    Int J Cancer. 2023 May 29. doi: 10.1002/ijc.34573.
    PubMed     Abstract available
    
    
    
52. GRIGUOLO G, Aldegheri V, Bottosso M, Pittaro A, et al
    Radiological response of leptomeningeal metastases according to revised RANO criteria is associated with overall survival in breast cancer patients.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34571.
    PubMed     Abstract available
    
    
    
53. SYLEOUNI ME, Karavasiloglou N, Manduchi L, Wanner M, et al
    Predicting second breast cancer among women with primary breast cancer using machine learning algorithms, a population-based observational study.
    Int J Cancer. 2023 May 27. doi: 10.1002/ijc.34568.
    PubMed     Abstract available
    
    
    
54. KRISTIANSEN MF, Mikkelsen RM, Kristiansdottir T, Andorsdottir G, et al
    Cancer survival in the Faroe Islands over the last 50 years compared to the other Nordic countries.
    Int J Cancer. 2023;152:2090-2098.
    PubMed     Abstract available
    
    
    April 2023
55. KANNAN S, Cheng VWT
    Nanoparticle drug delivery to target breast cancer brain metastasis: Current and future trends.
    Int J Cancer. 2023 Apr 25. doi: 10.1002/ijc.34542.
    PubMed     Abstract available
    
    
    
56. RANTALA JNJ, Heikkinen SMM, Hirvonen EM, Tanskanen T, et al
    Familial aggregation of early-onset cancers in early-onset breast cancer families.
    Int J Cancer. 2023 Apr 19. doi: 10.1002/ijc.34538.
    PubMed     Abstract available
    
    
    
57. JERARD C, Madhusudanan P, Swamy A, Ravikumar K, et al
    Secretome mediated interactions between sensory neurons and breast cancer cells.
    Int J Cancer. 2023 Apr 17. doi: 10.1002/ijc.34529.
    PubMed     Abstract available
    
    
    
58. KREGTING LM, van Ravesteyn NT, Chootipongchaivat S, Heijnsdijk EAM, et al
    Cumulative risks of false positive recall and screen-detected breast cancer after multiple screening examinations.
    Int J Cancer. 2023 Apr 10. doi: 10.1002/ijc.34530.
    PubMed     Abstract available
    
    
    
59. VAN STEENHOVEN JEC, van Maaren MC, Verreck EEF, Schipper RJ, et al
    Inequalities in the omission of axillary dissection in sentinel lymph node positive patients in the Netherlands: Innovative hospitals are early adopters of a de-escalating approach.
    Int J Cancer. 2023;152:1378-1387.
    PubMed     Abstract available
    
    
    
60. WAGENER R, Walter C, Auer F, Alzoubi D, et al
    The CHK2 kinase is recurrently mutated and functionally impaired in the germline of pediatric cancer patients.
    Int J Cancer. 2023;152:1388-1398.
    PubMed     Abstract available
    
    
    March 2023
61. SENKUS E, Delaloge S, Domchek SM, Conte P, et al
    Olaparib efficacy in patients with germline BRCA-mutated, HER2-negative metastatic breast cancer: subgroup analyses from the phase III OlympiAD trial.
    Int J Cancer. 2023 Mar 27. doi: 10.1002/ijc.34525.
    PubMed     Abstract available
    
    
    
62. QIN Z, Li J, Tam B, Sinha S, et al
    Ethnic-specificity, evolution origin and deleteriousness of Asian BRCA variation revealed by over 7500 BRCA variants derived from Asian population.
    Int J Cancer. 2023;152:1159-1173.
    PubMed     Abstract available
    
    
    
63. CARDOSO R, Hoffmeister M, Brenner H
    Breast cancer screening programmes and self-reported mammography use in European countries.
    Int J Cancer. 2023 Mar 8. doi: 10.1002/ijc.34494.
    PubMed     Abstract available
    
    
    February 2023
64. CHANG VC, Rhee J, Berndt SI, Moore SC, et al
    Serum perfluorooctane sulfonate and perfluorooctanoate and risk of postmenopausal breast cancer according to hormone receptor status: An analysis in the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial.
    Int J Cancer. 2023 Feb 26. doi: 10.1002/ijc.34487.
    PubMed     Abstract available
    
    
    
65. LIU S, van Dinther M, Hagenaars SC, Gu Y, et al
    Differential Optineurin expression controls TGFbeta signaling and is a key determinant for metastasis of triple negative breast cancer.
    Int J Cancer. 2023 Feb 23. doi: 10.1002/ijc.34483.
    PubMed     Abstract available
    
    
    
66. XIA C, Yu XQ, Chen W
    Measuring population-level cure patterns for cancer patients in the United States.
    Int J Cancer. 2023;152:738-748.
    PubMed     Abstract available
    
    
    
67. JIA G, Yang Y, Ping J, Xu S, et al
    Identification of target proteins for breast cancer genetic risk loci and blood risk biomarkers in a large study by integrating genomic and proteomic data.
    Int J Cancer. 2023 Feb 13. doi: 10.1002/ijc.34472.
    PubMed     Abstract available
    
    
    
68. GETU MA, Chen C, Addissie A, Seife E, et al
    The effect of cognitive behavioural therapy integrated with activity pacing on cancer-related fatigue, depression and quality of life among patients with breast cancer undergoing chemotherapy in Ethiopia: a randomised clinical trial.
    Int J Cancer. 2023 Feb 6. doi: 10.1002/ijc.34452.
    PubMed     Abstract available
    
    
    January 2023
69. GONZALEZ-CALLEJO P, Gener P, Diaz-Riascos ZV, Conti S, et al
    Extracellular vesicles secreted by triple negative breast cancer stem cells trigger pre-metastatic niche remodeling and metastatic growth in the lungs.
    Int J Cancer. 2023 Jan 27. doi: 10.1002/ijc.34447.
    PubMed     Abstract available
    
    
    
70. XU B, Ma F, Wang T, Wang S, et al
    A phase IIb, single arm, multicenter trial of sacituzumab govitecan in Chinese patients with metastatic triple-negative breast cancer who received at least two prior treatments.
    Int J Cancer. 2023 Jan 9. doi: 10.1002/ijc.34424.
    PubMed     Abstract available
    
    
    
71. KAR A, Medatwal N, Rajput K, Mandal S, et al
    Unique Sphingolipid Signature Identifies Luminal and Triple-Negative Breast Cancer Subtypes.
    Int J Cancer. 2023 Jan 5. doi: 10.1002/ijc.34423.
    PubMed     Abstract available
    
    
    December 2022
72. BOUCHERON P, Anele A, Offiah AU, Zietsman A, et al
    Reproductive history and breast cancer survival: findings from the African Breast Cancer - Disparities in Outcomes cohort and implications of Africa's fertility transition on breast cancer prognosis.
    Int J Cancer. 2022 Dec 22. doi: 10.1002/ijc.34411.
    PubMed     Abstract available
    
    
    November 2022
73. HEY J, Halperin C, Hartmann M, Mayer S, et al
    DNA methylation landscape of tumor-associated macrophages reveals pathways, transcription factors, and prognostic value relevant to triple-negative breast cancer patients.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34364.
    PubMed     Abstract available
    
    
    
74. LIN M, Jin Y, Lv H, Hu X, et al
    Incidence and prognostic significance of receptor discordance between primary breast cancer and paired bone metastases.
    Int J Cancer. 2022 Nov 21. doi: 10.1002/ijc.34365.
    PubMed     Abstract available
    
    
    
75. ARMAROLI P, Frigerio A, Correale L, Ponti A, et al
    A randomised controlled trial of digital breast tomosynthesis vs digital mammography as primary screening tests: Screening results over subsequent episodes of the Proteus Donna study.
    Int J Cancer. 2022;151:1778-1790.
    PubMed     Abstract available
    
    
    
76. ALCARAZ LB, Mallavialle A, Mollevi C, Boissiere-Michot F, et al
    SPARC in cancer-associated fibroblasts is an independent poor prognostic factor in non-metastatic triple-negative breast cancer and exhibits pro-tumor activity.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34345.
    PubMed     Abstract available
    
    
    
77. CAIRAT M, Pottegard A, Olesen M, Dossus L, et al
    Antiplatelet drugs and breast cancer risk in a large nationwide Danish case-control study.
    Int J Cancer. 2022 Nov 8. doi: 10.1002/ijc.34343.
    PubMed     Abstract available
    
    
    October 2022
78. MANOOCHEHRI M, Borhani N, Gerhauser C, Assenov Y, et al
    DNA methylation biomarkers for non-invasive detection of triple negative breast cancer using liquid biopsy.
    Int J Cancer. 2022 Oct 28. doi: 10.1002/ijc.34337.
    PubMed     Abstract available
    
    
    
79. CARIOLOU M, Abar L, Aune D, Balducci K, et al
    Postdiagnosis recreational physical activity and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34324.
    PubMed     Abstract available
    
    
    
80. BECERRA-TOMAS N, Balducci K, Abar L, Aune D, et al
    Postdiagnosis dietary factors, supplement use and breast cancer prognosis: Global Cancer Update Programme (CUP Global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34321.
    PubMed     Abstract available
    
    
    
81. TSILIDIS KK, Cariolou M, Becerra-Tomas N, Balducci K, et al
    Postdiagnosis body fatness, recreational physical activity, dietary factors and breast cancer prognosis: Global Cancer Update Programme (CUP Global) summary of evidence grading.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34320.
    PubMed     Abstract available
    
    
    
82. CHAN DSM, Vieira R, Abar L, Aune D, et al
    Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta-analysis.
    Int J Cancer. 2022 Oct 24. doi: 10.1002/ijc.34322.
    PubMed     Abstract available
    
    
    
83. LYNGE E, Vjeborg I, Lillholm M, Nielsen M, et al
    Breast Density and Risk of Breast Cancer.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34316.
    PubMed     Abstract available
    
    
    
84. BAHAR-SHANY K, Barnabas GD, Deutsch L, Deutsch N, et al
    Proteomic Signature for Detection of High Grade Ovarian Cancer in germline BRCA mutation carriers.
    Int J Cancer. 2022 Oct 10. doi: 10.1002/ijc.34318.
    PubMed     Abstract available
    
    
    September 2022
85. KANKURI-TAMMILEHTO M, Tervasmaki A, Kraatari-Tiri M, Rahikkala E, et al
    ATM c.7570G>C is a high-risk allele for breast cancer.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34305.
    PubMed     Abstract available
    
    
    
86. MAILLIEZ A, D'Hondt V, Lusque A, Caron O, et al
    Survival outcomes of metastatic breast cancer patients by germline BRCA1/2 status in a large multicenter real-world database.
    Int J Cancer. 2022 Sep 26. doi: 10.1002/ijc.34304.
    PubMed     Abstract available
    
    
    
87. WU J, Tan X
    The role of MTNR1B polymorphism on circadian rhythm-related cancer: A UK Biobank cohort study.
    Int J Cancer. 2022;151:888-896.
    PubMed     Abstract available
    
    
    August 2022
88. LOK SW, De Boer R, Baron-Hay S, Button P, et al
    Pertuzumab study in the neoadjuvant setting for HER2-positive nonmetastatic breast cancer in Australia (PeRSIA).
    Int J Cancer. 2022 Aug 16. doi: 10.1002/ijc.34245.
    PubMed     Abstract available
    
    
    
89. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Reply to: Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:651-652.
    PubMed    
    
    
    
90. BRAILLON A
    Comments on "Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modeled strategies".
    Int J Cancer. 2022;151:649-650.
    PubMed    
    
    
    
91. PEILA R, Lane DS, Shadyab AH, Saquib N, et al
    Healthy lifestyle index and the risk of ductal carcinoma in situ of the breast in the Women's Health Initiative.
    Int J Cancer. 2022;151:526-538.
    PubMed     Abstract available
    
    
    July 2022
92. MATTA M, Deubler E, Chajes V, Vozar B, et al
    Circulating plasma phospholipid fatty acid levels and breast cancer risk in the Cancer Prevention Study-II Nutrition Cohort.
    Int J Cancer. 2022 Jul 18. doi: 10.1002/ijc.34216.
    PubMed     Abstract available
    
    
    
93. KREGTING LM, Sankatsing VDV, Heijnsdijk EAM, de Koning HJ, et al
    Finding the optimal mammography screening strategy: A cost-effectiveness analysis of 920 modelled strategies.
    Int J Cancer. 2022;151:287-296.
    PubMed     Abstract available
    
    
    
94. BASSETT JK, MacInnis RJ, Yang Y, Hodge AM, et al
    Alcohol intake trajectories during the life course and risk of alcohol-related cancer: A prospective cohort study.
    Int J Cancer. 2022;151:56-66.
    PubMed     Abstract available
    
    
    June 2022
95. KARAVASILOGLOU N, Pestoni G, Kuhn T, Rohrmann S, et al
    Adherence to cancer prevention recommendations and risk of breast cancer in situ in the United Kingdom Biobank.
    Int J Cancer. 2022 Jun 20. doi: 10.1002/ijc.34183.
    PubMed     Abstract available
    
    
    
96. DESCHASAUX-TANGUY M, Barrubes Pinol L, Sellem L, Debras C, et al
    Dairy product consumption and risk of cancer: A short report from the NutriNet-Sante prospective cohort study.
    Int J Cancer. 2022;150:1978-1986.
    PubMed     Abstract available
    
    
    
97. RATOSA I, Dobnikar N, Bottosso M, Dieci MV, et al
    Leptomeningeal metastases in patients with human epidermal growth factor receptor 2 positive breast cancer: real-world data from a multicentric European cohort.
    Int J Cancer. 2022 Jun 6. doi: 10.1002/ijc.34135.
    PubMed     Abstract available
    
    
    
98. WU Z, Byrd DA, Wan Y, Ansong D, et al
    The oral microbiome and breast cancer and non-malignant breast disease, and its relationship with the fecal microbiome in the Ghana Breast Health Study.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34145.
    PubMed     Abstract available
    
    
    
99. HENNINGSEN MB, McWhan K, Dam VS, Mele M, et al
    Amplified Ca(2+) dynamics and accelerated cell proliferation in breast cancer tissue during purinergic stimulation.
    Int J Cancer. 2022 Jun 3. doi: 10.1002/ijc.34147.
    PubMed     Abstract available
    
    
    April 2022
100. ALLALI S, Carton M, Sarrade T, Querel O, et al
     CANTO-RT: Skin toxicities evaluation of a multicenter large prospective cohort of irradiated patients for early-stage breast cancer.
     Int J Cancer. 2022 Apr 30. doi: 10.1002/ijc.34057.
     PubMed     Abstract available
     
     
     
101. TRAN TXM, Kim S, Song H, Park B, et al
     Mammographic Breast Density, Body Mass Index, and Risk of Breast Cancer in Korean Women Aged 75 Years and Older.
     Int J Cancer. 2022 Apr 22. doi: 10.1002/ijc.34038.
     PubMed     Abstract available
     
     
     
102. BOUWER NI, Steenbruggen TG, Rier HN, Kitzen JJ, et al
     The effect of trastuzumab on cardiac function in patients with HER2-positive metastatic breast cancer and reduced baseline left ventricular ejection fraction.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34024.
     PubMed     Abstract available
     
     
     
103. CHEN F, Wen W, Long J, Shu X, et al
     Mendelian randomization analyses of 23 known and suspected risk factors and biomarkers for breast cancer overall and by molecular subtypes.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34026.
     PubMed     Abstract available
     
     
     
104. XIU M, Zhang P, Wang X, Fan Y, et al
     Survival outcomes for dose-dense paclitaxel plus carboplatin neoadjuvant versus standard adjuvant chemotherapy in stage II to III triple-negative breast cancer: a prospective cohort study with propensity-matched analysis.
     Int J Cancer. 2022 Apr 11. doi: 10.1002/ijc.34022.
     PubMed     Abstract available
     
     
     
105. RASHID MU, Muhammad N, Naeemi H, Shehzad U, et al
     Chasing the origin of 23 recurrent BRCA1 mutations in Pakistani breast and ovarian cancer patients.
     Int J Cancer. 2022 Apr 4. doi: 10.1002/ijc.34016.
     PubMed     Abstract available
     
     
     March 2022
106. XIE Y, Zhang Y, Xie K, Zhong X, et al
     Impact of time to initiation of postoperative radiotherapy after neoadjuvant chemotherapy on the prognosis of breast cancer: a retrospective cohort study in China.
     Int J Cancer. 2022 Mar 25. doi: 10.1002/ijc.34003.
     PubMed     Abstract available
     
     
     
107. WATT GP, Knight JA, Nguyen TL, Reiner AS, et al
     Association of contralateral breast cancer risk with mammographic density defined at higher-than-conventional intensity thresholds.
     Int J Cancer. 2022 Mar 22. doi: 10.1002/ijc.34001.
     PubMed     Abstract available
     
     
     February 2022
108. AYENI OA, O'Neil DS, Pumpalova YS, Chen WC, et al
     Impact of HIV infection on Survival among Women with Stage I-III Breast Cancer: Results from the South African Breast Cancer and HIV Outcomes Study.
     Int J Cancer. 2022 Feb 26. doi: 10.1002/ijc.33981.
     PubMed     Abstract available
     
     
     
109. HAFSTAETH V, Sokilde R, Hakkinen J, Larsson M, et al
     Regulatory networks and 5' partner usage of miRNA host gene fusions in breast cancer.
     Int J Cancer. 2022 Feb 19. doi: 10.1002/ijc.33972.
     PubMed     Abstract available
     
     
     
110. JOHANSSON A, Yiu-Lin Yu N, Iftimi A, Tobin NP, et al
     Clinical and Molecular Characteristics of ER-Positive Ultralow Risk Breast Cancer Tumors Identified by the 70-Gene Signature.
     Int J Cancer. 2022 Feb 18. doi: 10.1002/ijc.33969.
     PubMed     Abstract available
     
     
     
111. HA MJ, Raghavendra AS, Kettner NM, Qiao W, et al
     Palbociclib plus endocrine therapy significantly enhances overall survival of HR+/HER2- metastatic breast cancer patients compared to endocrine therapy alone in the second-line setting-a large institutional study.
     Int J Cancer. 2022 Feb 8. doi: 10.1002/ijc.33959.
     PubMed     Abstract available
     
     
     
112. FLUGELMAN AA, Burton A, Keinan-Boker L, Stein N, et al
     Correlation between cumulative mammographic density and age - specific incidence of breast cancer: a bi-ethnic study in israel.
     Int J Cancer. 2022 Feb 6. doi: 10.1002/ijc.33957.
     PubMed     Abstract available
     
     
     January 2022
113. SWERDLOW AJ, Bruce C, Cooke R, Coulson P, et al
     Risk of breast cancer in men in relation to weight change: a national case-control study in England and Wales.
     Int J Cancer. 2022 Jan 20. doi: 10.1002/ijc.33938.
     PubMed     Abstract available
     
     
     
114. MAILLIEZ A, Pigny P, Bogart E, Keller L, et al
     Is ovarian recovery after chemotherapy in young patients with early breast cancer influenced by controlled ovarian hyperstimulation for fertility preservation or tumor characteristics? Results of a prospective study in 126 patients.
     Int J Cancer. 2022 Jan 17. doi: 10.1002/ijc.33933.
     PubMed     Abstract available
     
     
     
115. GOTTSCHAU M, Bens A, Friis S, Cronin-Fenton D, et al
     Use of beta-blockers and risk of contralateral breast cancer.
     Int J Cancer. 2022 Jan 5. doi: 10.1002/ijc.33923.
     PubMed     Abstract available
     
     
     December 2021
116. ZHOU W, Jiang Y, Xu Y, Wang Y, et al
     Comparison of adverse drug reactions between tamoxifen and toremifene in breast cancer patients with different CYP2D6 genotypes: a propensity-score matched cohort study.
     Int J Cancer. 2021 Dec 26. doi: 10.1002/ijc.33919.
     PubMed     Abstract available
     
     
     
117. ABASCAL MF, Elia A, Alvarez M, Pataccini G, et al
     Progesterone receptor isoform ratio dictates antiprogestin/progestin effects on breast cancer growth and metastases: A role for NDRG1.
     Int J Cancer. 2021 Dec 22. doi: 10.1002/ijc.33913.
     PubMed     Abstract available
     
     
     
118. WEGE AK, Rom-Jurek EM, Jank P, Denkert C, et al
     mdm2 gene amplification is associated with luminal breast cancer progression in humanized PDX mice and a worse outcome of estrogen receptor positive disease.
     Int J Cancer. 2021 Dec 20. doi: 10.1002/ijc.33911.
     PubMed     Abstract available
     
     
     
119. PARK B
     Changes in weight and waist circumference during menopausal transition and postmenopausal breast cancer risk.
     Int J Cancer. 2021 Dec 18. doi: 10.1002/ijc.33906.
     PubMed     Abstract available
     
     
     November 2021
120. LOAP P, Loirat D, Berger F, Cao K, et al
     Combination of Olaparib with radiotherapy for triple-negative breast cancers: One-year toxicity report of the RADIOPARP Phase I trial.
     Int J Cancer. 2021;149:1828-1832.
     PubMed     Abstract available
     
     
     
121. KIM DS, Ahn HS, Kim HJ
     Statin use and incidence and mortality of breast and gynecology cancer: A cohort study using the National Health Insurance claims database.
     Int J Cancer. 2021 Nov 9. doi: 10.1002/ijc.33869.
     PubMed     Abstract available
     
     
     October 2021
122. WANG C, Gu K, Wang F, Cai H, et al
     Nut consumption in association with overall mortality and recurrence/disease-specific mortality among long-term breast cancer survivors.
     Int J Cancer. 2021 Oct 19. doi: 10.1002/ijc.33824.
     PubMed     Abstract available
     
     
     
123. YE C, Zhou W, Wang F, Yin G, et al
     Prognostic Value of GILT Expression in Female Patients Diagnosed with Breast Cancer.
     Int J Cancer. 2021 Oct 14. doi: 10.1002/ijc.33843.
     PubMed     Abstract available
     
     
     September 2021
124. ZHANG L, Wu ZY, Li J, Lin Y, et al
     Neoadjuvant Docetaxel Plus Carboplatin Versus Epirubicin Plus Cyclophosphamide Followed by Docetaxel in Triple-Negative, Early-Stage Breast Cancer (NeoCART): Results from a Multicenter, Randomized Controlled, Open-Label Phase II Trial.
     Int J Cancer. 2021 Sep 30. doi: 10.1002/ijc.33830.
     PubMed     Abstract available
     
     
     
125. POISEUIL M, Tron L, Woronoff AS, Tretarre B, et al
     How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?
     Int J Cancer. 2021 Sep 14. doi: 10.1002/ijc.33803.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO Breast Cancer is free of charge.